210 related articles for article (PubMed ID: 14584082)
1. Estimation of an optimal radiotherapy utilization rate for breast carcinoma: a review of the evidence.
Delaney G; Barton M; Jacob S
Cancer; 2003 Nov; 98(9):1977-86. PubMed ID: 14584082
[TBL] [Abstract][Full Text] [Related]
2. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part II--carcinoma of the endometrium.
Delaney G; Jacob S; Barton M
Cancer; 2004 Aug; 101(4):682-92. PubMed ID: 15305397
[TBL] [Abstract][Full Text] [Related]
3. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part I--malignancies of the cervix, ovary, vagina and vulva.
Delaney G; Jacob S; Barton M
Cancer; 2004 Aug; 101(4):671-81. PubMed ID: 15305396
[TBL] [Abstract][Full Text] [Related]
4. Estimation of an optimal external beam radiotherapy utilization rate for head and neck carcinoma.
Delaney G; Jacob S; Barton M
Cancer; 2005 Jun; 103(11):2216-27. PubMed ID: 15856428
[TBL] [Abstract][Full Text] [Related]
5. Estimation of an optimal radiotherapy utilization rate for gastrointestinal carcinoma: a review of the evidence.
Delaney G; Barton M; Jacob S
Cancer; 2004 Aug; 101(4):657-70. PubMed ID: 15305395
[TBL] [Abstract][Full Text] [Related]
6. Estimating the optimal radiotherapy utilization for carcinoma of the central nervous system, thyroid carcinoma, and carcinoma of unknown primary origin from evidence-based clinical guidelines.
Delaney G; Jacob S; Barton M
Cancer; 2006 Jan; 106(2):453-65. PubMed ID: 16355366
[TBL] [Abstract][Full Text] [Related]
7. Estimation of an optimal radiotherapy utilization rate for melanoma: a review of the evidence.
Delaney G; Barton M; Jacob S
Cancer; 2004 Mar; 100(6):1293-301. PubMed ID: 15022299
[TBL] [Abstract][Full Text] [Related]
8. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines.
Delaney G; Jacob S; Featherstone C; Barton M
Cancer; 2005 Sep; 104(6):1129-37. PubMed ID: 16080176
[TBL] [Abstract][Full Text] [Related]
9. Establishing treatment benchmarks for mammography-screened breast cancer population based on a review of evidence-based clinical guidelines.
Delaney G; Shafiq J; Chappell G; Barton M
Cancer; 2008 May; 112(9):1912-22. PubMed ID: 18318431
[TBL] [Abstract][Full Text] [Related]
10. Estimating the optimal external-beam radiotherapy utilization rate for genitourinary malignancies.
Delaney G; Jacob S; Barton M
Cancer; 2005 Feb; 103(3):462-73. PubMed ID: 15612081
[TBL] [Abstract][Full Text] [Related]
11. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part II-leukemia and myeloma.
Featherstone C; Delaney G; Jacob S; Barton M
Cancer; 2005 Jan; 103(2):393-401. PubMed ID: 15593373
[TBL] [Abstract][Full Text] [Related]
12. Estimating the optimal utilization rates of radiotherapy for hematologic malignancies from a review of the evidence: part I-lymphoma.
Featherstone C; Delaney G; Jacob S; Barton M
Cancer; 2005 Jan; 103(2):383-92. PubMed ID: 15599937
[TBL] [Abstract][Full Text] [Related]
13. A comparison of surgical and radiotherapy breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal" therapy.
Fong A; Shafiq J; Saunders C; Thompson AM; Tyldesley S; Olivotto IA; Barton MB; Dewar JA; Jacob S; Ng W; Speers C; Delaney GP
Breast; 2012 Aug; 21(4):570-7. PubMed ID: 22425535
[TBL] [Abstract][Full Text] [Related]
14. Estimation of the optimal brachytherapy utilization rate in the treatment of carcinoma of the uterine cervix: review of clinical practice guidelines and primary evidence.
Thompson S; Delaney G; Gabriel GS; Jacob S; Das P; Barton M
Cancer; 2006 Dec; 107(12):2932-41. PubMed ID: 17109449
[TBL] [Abstract][Full Text] [Related]
15. Estimation of an optimal chemotherapy utilisation rate for breast cancer: setting an evidence-based benchmark for the best-quality cancer care.
Ng W; Delaney GP; Jacob S; Barton MB
Eur J Cancer; 2010 Mar; 46(4):703-12. PubMed ID: 20034784
[TBL] [Abstract][Full Text] [Related]
16. A comparison of systemic breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of "optimal" therapy.
Fong A; Shafiq J; Saunders C; Thompson A; Tyldesley S; Olivotto IA; Barton MB; Dewar JA; Jacob S; Ng W; Speers C; Delaney GP
Breast; 2012 Aug; 21(4):562-9. PubMed ID: 22297168
[TBL] [Abstract][Full Text] [Related]
17. Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project.
Bentzen SM; Heeren G; Cottier B; Slotman B; Glimelius B; Lievens Y; van den Bogaert W
Radiother Oncol; 2005 Jun; 75(3):355-65. PubMed ID: 16086915
[TBL] [Abstract][Full Text] [Related]
18. Estimation of an optimal chemotherapy utilisation rate for head and neck carcinoma: setting an evidence-based benchmark for the best-quality cancer care.
Ng W; Jacob S; Delaney G; Barton M
Eur J Cancer; 2009 Aug; 45(12):2150-9. PubMed ID: 19285857
[TBL] [Abstract][Full Text] [Related]
19. Estimating the lifetime utilization rate of radiotherapy in cancer patients: the Multicohort Current Utilization Table (MCUT) method.
Zhang-Salomons J; Mackillop WJ
Comput Methods Programs Biomed; 2008 Oct; 92(1):99-108. PubMed ID: 18676052
[TBL] [Abstract][Full Text] [Related]
20. Estimation of an optimal utilisation rate for palliative radiotherapy in newly diagnosed cancer patients.
Jacob S; Wong K; Delaney GP; Adams P; Barton MB
Clin Oncol (R Coll Radiol); 2010 Feb; 22(1):56-64. PubMed ID: 19969443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
